Navigation Links
Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
Date:5/25/2011

ncer patients. Two drugs from the CDP initiative are already in early phase trials.

CEN-209 is currently in pre-clinical development. Under the terms of the partnership, Cancer Research UK's Drug Development Office will complete pre-clinical development of the drug and take it through the first Phase I clinical trial, which will be conducted through the charity's Experimental Cancer Medicine Centres.

After the Phase I trial Centella will have the exclusive option to buy back the clinical trial data and conduct further clinical studies towards approval of CEN-209.  If Centella doesn't exercise its option, the rights to the programme will be transferred to Cancer Research Technology to secure an alternative partner with the goal of making it possible for the drug to reach cancer patients.  

Dr. Thorsten Melcher, president of Centella, said: "We are very pleased to work in this public-private partnership with the experts from Cancer Research UK to advance CEN-209. The drug development experience of Cancer Research UK is very well respected and critical to evaluate the potential of CEN-209 for attacking hypoxic tumours for which few effective treatments are available today. Centella is particularly excited to launch this important project that may make radiotherapy even more effective, and to do it in the year that the United Kingdom has dedicated to raising awareness for radiotherapy."

2011 was designated "The Year of Radiotherapy" in the UK, to help raise awareness of the treatment and highlight the progress made over the last century.

Dr. Ian Walker, senior licensing manager at Cancer Research UK's Drug Development Office, said: "Through this exciting partnership, we are taking a completely new drug which could treat a range of cancer types into clinical trials - bringing new hope for thousands o
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
(Date:7/13/2014)... July 13, 2014 A Massachusetts couple ... the cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... story to federal regulators, as they presented poignant testimony ... & Drug Administration (FDA) advisory panel meeting convened to ... to the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. ... extremely beautiful. Recently, the company has announced its new ... What’s more, all these outfits are available at discounted ... Additionally, the supplier is now offering similar discounts for ... it has many other designs for sale, including flower ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review recently updated ... what to do to eliminate the root cause of ... review that readers can easily learn what foods to avoid ... Vkool also informs in its Kidney Disease Solution review that ... naturally. The book consists of a collection of natural remedies ...
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 ... Ken Woolcott, who commented, “As a parent of a ... the underserved need in the Seattle community for contemporary ... will provide an important alternative to students and families ... the best practices and environment for special education. We ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
... study says , , TUESDAY, Oct. 28 (HealthDay News) -- A ... to the immune system of people aged 65 and older ... study that included nearly 4,000 people. , Blood tests showed ... the standard flu vaccine had 30 percent to 80 percent ...
... Trials on Schedule, HAIKOU CITY, China, ... ("China Pharma") (OTC Bulletin Board: CPHI), which,develops, ... in China, announced today that its novel ... China,s State Food and Drug,Administration (SFDA) to ...
... December 5, 2008, Alta,Bates Summit Medical Center,s Markstein ... their Summit Campus (3100 Summit Street,Oakland, CA, 94609). ... Foundation, a San Francisco Bay Area non-profit dedicated ... a time. Sponsoring this screening,is part of the ...
... SAN FRANCISCO, Calif., Oct. 29 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... vice president and chief operating officer, will present,a company ... November 3 at 3:20 p.m. EST at The Waldorf ... live audio webcast or the subsequent archived recording,log on ...
... 2008 at this year,s liver meeting ... SAN FRANCISCO, Oct. 29 Two studies presented at the,annual ... Diseases,paint a different picture of survival based on racial group ... the Baylor College of Medicine used a United Network for,Organ ...
... GAAP diluted earnings per share from continuing operations decline 16 ... basis ... ... a,global provider of products and services that improve the safety and,productivity of health ...
Cached Medicine News:Health News:High-Dose Flu Shot Benefits Elderly 2Health News:China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination 2Health News:China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination 3Health News:Lazarex Cancer Foundation Sponsors Community Colorectal Cancer Screening at Alta Bates Summit Medical Center 2Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 2Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 3Health News:Cardinal Health Reports First Quarter Results 2Health News:Cardinal Health Reports First Quarter Results 3Health News:Cardinal Health Reports First Quarter Results 4Health News:Cardinal Health Reports First Quarter Results 5Health News:Cardinal Health Reports First Quarter Results 6Health News:Cardinal Health Reports First Quarter Results 7Health News:Cardinal Health Reports First Quarter Results 8Health News:Cardinal Health Reports First Quarter Results 9Health News:Cardinal Health Reports First Quarter Results 10Health News:Cardinal Health Reports First Quarter Results 11Health News:Cardinal Health Reports First Quarter Results 12Health News:Cardinal Health Reports First Quarter Results 13Health News:Cardinal Health Reports First Quarter Results 14Health News:Cardinal Health Reports First Quarter Results 15Health News:Cardinal Health Reports First Quarter Results 16Health News:Cardinal Health Reports First Quarter Results 17Health News:Cardinal Health Reports First Quarter Results 18Health News:Cardinal Health Reports First Quarter Results 19Health News:Cardinal Health Reports First Quarter Results 20Health News:Cardinal Health Reports First Quarter Results 21Health News:Cardinal Health Reports First Quarter Results 22Health News:Cardinal Health Reports First Quarter Results 23
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: